行情

NKTR

NKTR

内克塔治疗
NASDAQ

实时行情|Nasdaq Last Sale

20.22
+0.12
+0.60%
盘后: 20.21 -0.01 -0.05% 19:19 09/19 EDT
开盘
20.13
昨收
20.10
最高
20.40
最低
19.81
成交量
176.39万
成交额
--
52周最高
62.70
52周最低
16.56
市值
35.44亿
市盈率(TTM)
-8.3056
分时
5日
1月
3月
1年
5年

分析师评级

13位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NKTR 新闻

  • Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm
  • GlobeNewswire.1天前
  • NKTR, PS & BRFRF, BRFRY - Class Action Update - Bronstein, Gewirtz & Grossman, LLC
  • ACCESSWIRE.1天前
  • Healthcare And Biotechnology Dashboard - Update
  • Seeking Alpha - Article.1天前
  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
  • GlobeNewswire.2天前

更多

所属板块

生物技术和医学研究
+0.01%
制药与医学研究
+0.41%

热门股票

名称
价格
涨跌幅

NKTR 简况

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.
展开

Webull提供Nektar Therapeutics的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。